CN114755403A - Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer - Google Patents
Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer Download PDFInfo
- Publication number
- CN114755403A CN114755403A CN202210218995.3A CN202210218995A CN114755403A CN 114755403 A CN114755403 A CN 114755403A CN 202210218995 A CN202210218995 A CN 202210218995A CN 114755403 A CN114755403 A CN 114755403A
- Authority
- CN
- China
- Prior art keywords
- enhancer
- chemiluminescent
- indole
- acid
- phenothiazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003623 enhancer Substances 0.000 title claims abstract description 43
- 150000002475 indoles Chemical class 0.000 title claims abstract description 20
- 229940054051 antipsychotic indole derivative Drugs 0.000 title claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 34
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims abstract description 23
- -1 phenothiazine compound Chemical class 0.000 claims abstract description 19
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 15
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 9
- 239000011734 sodium Substances 0.000 claims abstract description 9
- 239000003617 indole-3-acetic acid Substances 0.000 claims abstract description 8
- 229950000688 phenothiazine Drugs 0.000 claims abstract description 8
- 229930192334 Auxin Natural products 0.000 claims abstract description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 7
- 239000002363 auxin Substances 0.000 claims abstract description 7
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 claims abstract description 6
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims abstract description 4
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 238000003119 immunoblot Methods 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 3
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000002990 phenothiazines Chemical class 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000012744 reinforcing agent Substances 0.000 abstract description 3
- 230000005540 biological transmission Effects 0.000 abstract description 2
- 238000004020 luminiscence type Methods 0.000 description 16
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 7
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000504 luminescence detection Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- LVAZRHUNTBHMRT-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid cyclohexane Chemical compound C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O.C1CCCCC1 LVAZRHUNTBHMRT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WGLQHUKCXBXUDV-UHFFFAOYSA-L 3-aminophthalate Chemical compound NC1=CC=CC(C([O-])=O)=C1C([O-])=O WGLQHUKCXBXUDV-UHFFFAOYSA-L 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- QJWQYVJVCXMTJP-UHFFFAOYSA-N 4-pyridin-4-ylmorpholine Chemical compound C1COCCN1C1=CC=NC=C1 QJWQYVJVCXMTJP-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000008061 acetanilides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The invention belongs to the field of chemiluminescent reagents, and discloses an application of indole derivatives as a chemiluminescent enhancer and a kit containing the enhancer. In the application, the indole derivative is used as a second reinforcing agent and is combined with a phenothiazine compound as a first reinforcing agent; further, the phenothiazine compound is selected from one of 3- (10-phenothiazinyl) propane-1-sodium sulfonate, 10- (3-dimethylaminopropyl) phenothiazine and derivatives thereof; further, the indole derivatives are selected from one or more of tryptophan, 5-hydroxytryptamine, auxin and indole-3-acetic acid. The invention utilizes the combination of phenothiazine compounds and indole derivatives to exert synergistic effect, thereby not only improving the brightness of the luminescent reagent, but also prolonging the luminescent time due to the mutual transmission of electrons.
Description
Technical Field
The invention belongs to the field of chemiluminescent reagents, and discloses an application of indole derivatives as a chemiluminescent enhancer and a kit containing the enhancer.
Background
Horse Radish Peroxidase (HRP) catalyzed luminol and peroxy compound chemiluminescence reaction is widely applied to detection and analysis of antigens and antibodies, especially enzyme-linked immunosorbent assay (ELISA) and immunoblotting assay. Horseradish peroxidase was conjugated to an antigen or antibody, and the amount of antigen or antibody was analyzed indirectly by measuring the amount of HRP.
Luminol as a classical chemiluminescent reaction, a number of compounds have been successfully used to enhance HRP-induced chemiluminescence, including: p-iodophenol, p-coumarin and other phenolic enhancers, and acetanilides and phenothiazines besides the phenolic enhancers, wherein the phenothiazines belong to the more newly discovered enhancers. Phenothiazines have a stronger luminescence intensity compared to the remaining luminescence enhancers, especially a stronger luminescence intensity and luminescence stability when an enhancer such as imidazole, 4-morpholinopyridine is added as a second enhancer, i.e., a co-enhancer.
However, the current phenothiazine-type enhancers and the reported second enhancers have a large increase in brightness, but poor stability. Therefore, on the basis of the theory of new enhancers and second enhancers, it is still necessary to develop new enhancer combinations to achieve improved stability of chemiluminescence without reducing the sensitivity of chemiluminescence too much, ensuring that the luminescence intensity decays less than 10% within two hours.
Disclosure of Invention
In view of the above situation, the present invention discloses the use of indole derivatives as a chemiluminescence enhancer, and a kit comprising the enhancer.
The technical scheme of the invention is as follows:
use of an indole derivative as a second enhancer in combination with a phenothiazine compound as a first enhancer as a chemiluminescence enhancer.
In the above use, the phenothiazine compound is selected from one of sodium 3- (10-phenothiazinyl) propane-1-sulfonate, 10- (3-dimethylaminopropyl) phenothiazine and a derivative thereof.
Further, in the above use, the indole derivative is selected from one or more of tryptophan, 5-hydroxytryptamine, auxin and indole-3-acetic acid.
Further, in the above use, the final concentration of the indole derivative in the chemiluminescent reagent is between 1 and 30 mM.
Further, a chemiluminescent reagent comprising a phenothiazine compound as a first enhancer; indole derivatives as second enhancers; luminol, isoluminol or a luminol-related derivative as a luminescent substrate.
Further, a chemiluminescence kit comprises the chemiluminescence reagent.
Furthermore, the chemiluminescence kit comprises a solution A and a solution B,
the solution A comprises a chemiluminescent reagent, a buffering agent A and a humectant;
the liquid B comprises a hyperoxidant, a stabilizer and a buffer B.
Furthermore, the chemiluminescence kit can be used for preparing a fluorescent material,
the liquid A comprises:
1) and a luminescent substrate: selected from luminol, isoluminol or a luminol-related derivative;
2) and a first enhancer: one selected from 3- (10-phenothiazinyl) propane-1-sodium sulfonate, 10- (3-dimethylaminopropyl) phenothiazine and derivatives thereof;
3) and a second enhancer: one or more selected from tryptophan, 5-hydroxytryptamine, auxin, and indole-3-acetic acid;
4) and a buffer A: a buffer at a pH between 8 and 9.5;
the liquid B comprises:
1) and a peroxide: one selected from hydrogen peroxide, urea hydrogen peroxide or perborate;
2) and a stabilizer: one selected from ethylenediamine tetraacetic acid, cyclohexane ethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid and diethyl triaminepentaacetic acid;
3) and a buffer B: the pH value is 2-6, and is selected from acetic acid, benzoic acid, phosphoric acid, and citric acid.
Further, in the above chemiluminescence kit, the solution a further comprises: 5) and (3) a humectant: one or more selected from glycerol, hyaluronic acid and propylene glycol.
Further, the chemiluminescence kit preferably comprises the following components:
the liquid A and the liquid B are mixed before use, and the mixing proportion is determined according to the final concentration and is not limited to a specific mixing proportion.
Wherein the solution A comprises the following components:
1) and a luminescent substrate comprising luminol, isoluminol and luminol-related derivatives, wherein the dosage is as follows: between 0.5 and 10mM
2) And a first enhancer: belongs to phenothiazine compounds, one of 3- (10-phenothiazinyl) propane-1-sodium sulfonate, 10- (3-dimethylaminopropyl) phenothiazine and derivatives thereof, and the dosage is as follows: between 1 and 20 mM.
3) And a second enhancer: belongs to indole derivatives, mainly comprisesTryptophan5-hydroxytryptamine, auxin, and indole-3-acetic acid in an amount of 1-30 mM.
4) And a buffer A: mainly selected from common buffer solutions with the buffering range between pH8-9.5, including Tris-HCl, borate and the like, and the dosage is as follows: 10-200 mM.
5) And (3) a humectant: comprises glycerol, hyaluronic acid and propylene glycol, and the dosage is between 500 and 2000 mM.
Wherein the liquid B comprises the following components:
1) the peroxidating agent comprises one of hydrogen peroxide, urea hydrogen peroxide and perborate, and the dosage of the peroxidating agent is between 0.01mM and 10 mM.
2) The stabilizer is also a chelating agent and is one of ethylenediamine tetraacetic acid, cyclohexane ethylenediamine tetraacetic acid, ethylene glycol tetraacetic acid and diethyl triaminepentaacetic acid, and the dosage is 0.001mM-0.1 mM.
3) And a buffer B with a pH value ranging from 2 to 6, wherein the buffer B is one selected from acetic acid, benzoic acid, phosphoric acid and citric acid and is used in an amount of 10mM to 100 mM.
Further, the chemiluminescence reagent or chemiluminescence kit is used for preparing a kit for an immunoblotting experiment or an enzyme-linked immunosorbent assay.
The invention has the following beneficial effects:
in the prior art, the single luminol reacts with the peroxide compound, so that the quantum yield of the luminescence reaction is low and the reaction speed is high. The addition of the enhancer makes the chemiluminescence oxidation faster, brighter and more stable. According to the existing chemiluminescence principle, the mechanism can be called as 'ping-pong' mechanism, horseradish peroxidase is activated into an oxidation intermediate through hydrogen peroxide in the luminescence process, an enhancer is oxidized into a free radical product through the oxidation intermediate of the enzyme, the product can be in reversible reaction with luminol molecules, finally, after the luminol is subjected to multi-step basic reaction, the excited state of 3-aminophthalate is generated along with the generation of molecular nitrogen, and blue light with the wavelength of 425nm is released when the luminol returns to the ground state. The principle of the synergistic reaction is shown in the attached FIG. 1, and can be referred to in the literature (Development of a high purity biochemical enzyme immunoassay enhanced luminescence as substrate.)
The invention provides a sensitive chemiluminescence reagent with stable luminescence, which is used for detecting horseradish peroxidase in a sample. The invention highlights the fact that by proposing a new second enhancer, in combination with the already reported first enhancer, the light emitted by the system is stabilized, ensuring that the sensitivity is not reduced too much. The new second enhancer is DL-tryptophan or L-tryptophan, and can be extended to indole derivatives such as 5-hydroxytryptamine, auxin, indole-3-acetic acid, etc.
On the basis of the formula, glycerol, hyaluronic acid, propylene glycol and the like are added into the reagent formula, so that the density of the substances is higher than that of pure water, and the deep layer bonding of the surface of the reagent solid phase carrier is increased in actual use; meanwhile, the moisture absorption and moisture retention function is achieved, so that long-time detection can be facilitated, and the problem of reagent volatilization is not worried about.
According to the invention, the phenothiazine compound and the indole derivative are used in combination, and the synergistic effect is exerted by combining the two reinforcing agents according to the 'ping-pong theory', so that the brightness is improved, and the luminescence time is prolonged due to the mutual transmission of electrons. Furthermore, the invention can also add humectant at the same time, which ensures the stability of the incubation of the reagent on the peroxidase, and simultaneously can prevent inaccurate luminescence detection result caused by excessive residual liquid of the carrier due to the increase of the density, and the improvement effect is most obvious particularly in an immunoblotting experiment. Therefore, the luminescent reagent can be suitable for various enzyme-linked immunosorbent assays and immunoblotting assays.
Drawings
FIG. 1 is a principle of a synergistic reaction;
fig. 2 is a luminescence detection diagram in embodiment 3, and the sample size on each diagram is respectively 100ug, 50ug, 25ug, 12.5ug, 6.25ug and 3.125ug from left to right.
Detailed Description
The test methods used in the following examples are all conventional methods unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
The invention relates to a high-sensitivity signal-stable chemiluminescent reagent, which comprises a reagent A liquid and a reagent B liquid;
formulation I
Solution A:
luminol 5mM
Sodium 3- (10-phenothiazinyl) propane-1-sulfonate 10mM
5-hydroxytryptamine 10mM
Tris 100mM
The pH was adjusted to between 8.5 and 8.8 using 6M hydrochloric acid.
And B, liquid B:
0.01mM hydrogen peroxide
EDTA 0.002mM
Glycerol 300mM
Hyaluronic acid 0.1mM
Acetic acid-sodium acetate buffer 50mM pH 5.0-5.5
Formulation II
Solution A:
luminol 2mM
Sodium 3- (10-phenothiazinyl) propane-1-sulfonate 10mM
Tryptophan 15mM
Tris 100mM
The pH was adjusted to between 8.5 and 8.8 using 6M hydrochloric acid.
And B, liquid B:
0.01mM hydrogen peroxide
EDTA 0.002mM
Glycerol 300mM
Sodium benzoate solution 50mM pH 2-4
The formula III is as follows:
solution A:
luminol 10mM
Sodium 3- (10-phenothiazinyl) propane-1-sulfonate 10mM
Tryptophan 5mM
Indole-3-acetic acid 5mM
Tris 100mM
The pH was adjusted to between 8.5 and 8.8 using 6M hydrochloric acid.
And B, liquid B:
0.01mM hydrogen peroxide
EDTA 0.002mM
Propylene glycol 20mM
Sodium benzoate solution 50mM pH 2-4
The above formula is representative of one, and the compounds listed and corresponding concentration ranges can be combined into a formula.
Example 1
In this example, antigen-antibody detection was performed using formulation one.
The kit can be used for detecting various in-vitro antibody antigens, the antigen antibodies are coated in a white or black opaque polystyrene microporous plate, and then the content of the antigen or the antibody is detected through a coupled HRP marker, taking common alpha-fetoprotein (AFP) as an example.
The reference substance is a commercial alpha fetoprotein quantitative detection kit (chemiluminescence immunoassay (panoramic life)), a reagent for detecting and establishing a standard curve in a calibrator is used, the reagent is coated in a white polystyrene micropore plate, the concentration range is 0-500ng/ml, the reagent is incubated by using a corresponding antibody coupled with HRP, the luminous intensity of the reagent is detected by using a BioTek Synergy H1 full-function micropore plate detector, micropores with the concentration of 250ng/ml are selected, and the luminous value is detected once every 5min, and the measurement is carried out for 2 hours.
Results table 1 shows the concentration of alpha-fetoprotein (AFP) and the corresponding luminescence intensity,
TABLE 1 concentration of alpha-fetoprotein (AFP) and corresponding luminescence intensity
| Concentration of calibrator (ng/ml) | |
Reference substance |
| 0 | 749 | 1325 |
| 15.625 | 28346 | 29259 |
| 31.25 | 61263 | 51918 |
| 62.5 | 136642 | 106476 |
| 125 | 270878 | 241821 |
| 250 | 537853 | 538905 |
| 500 | 1352011 | 1015941 |
According to the above luminescence results, in the example formula I and the reference substance, the washing related to the linear fitting of the protein concentration and the luminescence value data is more than 0.95. However, the luminous value of the same concentration is larger than that of the contrast, and the standard curve has larger slope, which indicates that the detection result of the formula has higher accuracy and sensitivity.
Example 2
The second formula is used for comparison of the chemiluminescence reagent thermal stability experiment
Preparing reagent according to formula II, placing the obtained reagent at 37 deg.C for 4 days, 8 days, and 12 days, respectively, comparing with the luminous reagent prepared on the same day, directly using horse radish peroxidase dissolved in physiological saline, and diluting to 1X10-15And (3) taking 100ul of the luminescent liquid A and the luminescent liquid B which are different in standing days respectively for standby application, mixing, adding the mixture into a white polystyrene micropore plate, and then adding the diluted horseradish peroxidase into each hole. The luminescence value was measured using a BioTek Synergy H1 full-function microplate detector. The results are shown in Table 2.
TABLE 2 chemiluminescence reagent thermal stability experiment
From the above results, it was found that the luminescent reagent is stable in properties and can be stored for a long period of time.
Example 3
In the embodiment, the third formula is used, and the detection effect of the western blot detection is realized
The specific operation process is as follows:
selecting mouse liver tissue, extracting protein with RIPA lysate, detecting protein concentration, and calculating protein adding amount of 100ug, 50ug, 25ug, 12.5ug, 6.25ug and 3.125ug for each well according to the detected protein concentration. Protein electrophoresis and membrane transfer were performed according to the conventional procedure using NC membrane, which was closed with skim milk powder and incubated with Histone H3 primary antibody overnight, followed by HRP-labeled secondary antibody and luminescence detection using a luminescence reagent. The selected control products were imported good-selling products: SuperSignal West Dura chemiluminescent substrate. In order to ensure that the result is always consistent, the same NC membrane is used in detection, and different luminous liquids are repeatedly used for detection and comparison.
As shown in FIG. 2, the exposure time was 30s, and the stability of the product of the present invention was slightly higher than that of the control.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art.
Claims (10)
1. Use of an indole derivative as a chemiluminescent enhancer characterized in that the indole derivative is used as a second enhancer in combination with a phenothiazine compound as a first enhancer.
2. The use according to claim 1, wherein the phenothiazine-like compound is selected from the group consisting of sodium 3- (10-phenothiazinyl) propane-1-sulfonate, 10- (3-dimethylaminopropyl) phenothiazine, and derivatives thereof.
3. The use according to claim 1, wherein the indole derivative is selected from one or more of tryptophan, 5-hydroxytryptamine, auxin or indole-3-acetic acid.
4. Use according to claim 1, wherein the final concentration of the indole derivative in the chemiluminescent reagent is between 1 and 30 mM.
5. A chemiluminescent reagent comprising a phenothiazine compound as a first enhancer; indole derivatives as second enhancers; luminol, isoluminol or a luminol-related derivative as a luminescent substrate.
6. A chemiluminescent kit comprising the chemiluminescent reagent of claim 5.
7. A chemiluminescent kit according to claim 6 comprises solution A and solution B, wherein the solution A comprises a chemiluminescent reagent, a buffer A and a humectant;
the liquid B comprises a hyperoxidant, a stabilizer and a buffer B.
8. A chemiluminescent kit according to claim 7,
the liquid A comprises:
1) and a luminescent substrate: selected from luminol, isoluminol or a luminol-related derivative;
2) and a first enhancer: one selected from 3- (10-phenothiazinyl) propane-1-sodium sulfonate, 10- (3-dimethylaminopropyl) phenothiazine and derivatives thereof;
3) and a second enhancer: one or more selected from tryptophan, 5-hydroxytryptamine, auxin, and indole-3-acetic acid;
4) and a buffer A: a buffer at a pH between 8 and 9.5;
the liquid B comprises:
1) and a peroxide: one selected from hydrogen peroxide, urea hydrogen peroxide or perborate;
2) and a stabilizer: one selected from ethylenediamine tetraacetic acid, cyclohexane ethylenediamine tetraacetic acid, ethylene glycol tetraacetic acid, diethyl triamine pentaacetic acid;
3) and a buffer B: the pH value is 2-6, and is selected from acetic acid, benzoic acid, phosphoric acid, and citric acid.
9. The chemiluminescent kit according to claim 8, wherein the solution A further comprises: 5) and a humectant: one or more selected from glycerol, hyaluronic acid and propylene glycol.
10. Use of a chemiluminescent reagent or chemiluminescent kit of any one of claims 5 to 9 in the manufacture of a kit for immunoblotting or enzyme-linked immunosorbent assays.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210218995.3A CN114755403A (en) | 2022-03-08 | 2022-03-08 | Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210218995.3A CN114755403A (en) | 2022-03-08 | 2022-03-08 | Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114755403A true CN114755403A (en) | 2022-07-15 |
Family
ID=82325434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210218995.3A Pending CN114755403A (en) | 2022-03-08 | 2022-03-08 | Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114755403A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272108A1 (en) * | 2004-05-21 | 2005-12-08 | Bhanu Kalra | Stabilized two component system for chemiluminescent assay in immunodiagnostics |
| JP2011043447A (en) * | 2009-08-24 | 2011-03-03 | Kikkoman Corp | Emission enhancement method of peroxidase chemiluminescent reaction |
| US20160266045A1 (en) * | 2015-03-13 | 2016-09-15 | Li-Cor, Inc. | Fluorogenic and chromogenic substrate |
| CN112198309A (en) * | 2020-09-29 | 2021-01-08 | 上海雅酶生物医药科技有限公司 | Chemiluminescence substrate detection kit with high sensitivity and stable signal |
| CN112400113A (en) * | 2018-07-13 | 2021-02-23 | 3M创新有限公司 | Specific binding chemiluminescence assay |
-
2022
- 2022-03-08 CN CN202210218995.3A patent/CN114755403A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272108A1 (en) * | 2004-05-21 | 2005-12-08 | Bhanu Kalra | Stabilized two component system for chemiluminescent assay in immunodiagnostics |
| JP2011043447A (en) * | 2009-08-24 | 2011-03-03 | Kikkoman Corp | Emission enhancement method of peroxidase chemiluminescent reaction |
| US20160266045A1 (en) * | 2015-03-13 | 2016-09-15 | Li-Cor, Inc. | Fluorogenic and chromogenic substrate |
| CN112400113A (en) * | 2018-07-13 | 2021-02-23 | 3M创新有限公司 | Specific binding chemiluminescence assay |
| CN112198309A (en) * | 2020-09-29 | 2021-01-08 | 上海雅酶生物医药科技有限公司 | Chemiluminescence substrate detection kit with high sensitivity and stable signal |
Non-Patent Citations (2)
| Title |
|---|
| 刘丽珍等: "鲁米诺-铁氰化钾化学发光体系测定吲哚乙酸", 《山西师范大学学报》, vol. 23, no. 2, 30 June 2009 (2009-06-30), pages 74 - 77 * |
| 吴秀明等: "铜纳米簇催化鲁米诺化学发光体系的研究及应用", 化学研究与应用, vol. 28, no. 08, 15 August 2016 (2016-08-15), pages 1070 - 1074 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4729950A (en) | Enhanced luminescent or luminometric assay | |
| AU2011202658B2 (en) | Method for increasing and regulating light emission from a chemiluminescent reaction | |
| US20050272108A1 (en) | Stabilized two component system for chemiluminescent assay in immunodiagnostics | |
| EP0505198B1 (en) | A method of enhancing a luminescent reaction, luminometric assay and kits for use in the same | |
| US6602679B2 (en) | Stabilized formulations for chemiluminescent assays | |
| JPH0648997B2 (en) | Enhanced chemiluminescent reaction and diagnostic assay | |
| Kuroda et al. | Lophine derivatives and analogues as new phenolic enhancers for the luminol–hydrogen peroxide–horseradish peroxidase chemiluminescence system | |
| CN105806830A (en) | Stable HRP (Horseradish Peroxidase) enzyme-catalyzed chemiluminescence substrate solution as well as preparation method and application thereof | |
| EP0235970A1 (en) | Luminescent analyses with enhanced storage stability | |
| CN114755403A (en) | Use of indole derivatives as chemiluminescence enhancer and kit containing enhancer | |
| Williams et al. | A homogeneous assay for biotin based on chemiluminescence energy transfer | |
| JPH066074B2 (en) | Method for increasing quantum yield during oxidation of luminol or 7-dialkylaminonaphthalene-1,2-dicarboxylic acid-hydrazide and reagent for peroxidase measurement | |
| CN111454718A (en) | Ultrasensitive chemiluminescent substrates for peroxidases | |
| US20020192736A1 (en) | Assay of peroxidase activity | |
| NL2010244C2 (en) | Methods and means to enhance the sensitivity of a chemiluminescent reaction. | |
| JPH05505513A (en) | Luminescent or luminometric test | |
| JP3776229B2 (en) | Chemiluminescent reagent and method for producing the same | |
| JP3792898B2 (en) | Method for measuring peroxidase activity | |
| JPH05140146A (en) | Stabilizing agent of 1,2-dioxetane derivative | |
| JP3815905B2 (en) | Enzyme immunoassay | |
| CN110927371A (en) | Stable and efficient HRP enzymatic chemiluminescence substrate solution as well as preparation method and application thereof | |
| JP3746381B2 (en) | Chemiluminescent enzyme immunoassay method | |
| JP4028648B2 (en) | Method for measuring peroxidase activity | |
| TW202307174A (en) | Composition, stabilization method, method for measuring amount of luminescence, and stabilizer for luminescent substrate | |
| JP3792908B2 (en) | Method for measuring peroxidase activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |